Physician profile
Mark R Pipher
NPI 1932356805
$5,276.73
in general payments reported to CMS, 2019-2025
48 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $314 · 2021: $1,100 · 2022: $483 · 2023: $905 · 2024: $751 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Travel and Lodging: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.32 |
| Travel and Lodging | $269.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.43 | 2021-2025 | |
| Smith+Nephew, INC. | $606.65 | 2019-2025 | Salto Talaris Total Ankle Prosthesis, Cadence, Renasys Touch |
| Stryker Corporation | $533.88 | 2021-2023 | Salvation |
| Paragon 28, INC. | $465.68 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $342.14 | 2019-2021 | |
| Polynovo North America LLC | $330.46 | 2022-2025 | Novosorb Btm |
| Bioventus LLC | $207.48 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Averitas Pharma INC. | $178.30 | 2024 | Qutenza |
| Kci USA, INC. | $139.86 | 2019-2023 | Promogran Prisma, Activ.A.C., V.A.C. Veraflo |
| Paratek Pharmaceuticals, INC. | $137.30 | 2021-2025 | Nuzyra |
| Ortho Solutions INC | $115.74 | 2019 | |
| Amgen INC. | $113.32 | 2024-2025 | Krystexxa |
| Alfasigma USA, INC. | $94.59 | 2021-2022 | |
| Abbott Laboratories | $92.39 | 2019-2025 | Proclaim |
| Orthofix Medical, INC. | $89.56 | 2019-2025 | Physio-Stim |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $87.84 | 2019-2022 | |
| Tactile Systems Technology INC | $87.63 | 2019-2020 | |
| Depuy Synthes Sales INC. | $85.23 | 2025 | Motoband, Na, Speedtrap |
| Advanced Oxygen Therapy INC. | $75.27 | 2024-2025 | Topical Oxygen Chamber For Extremities |
| Djo, LLC | $63.68 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.25 | 2019-2022 | |
| Organogenesis INC. | $57.80 | 2019-2022 | |
| Arteriocyte Medical Systems, INC. | $46.30 | 2022 | |
| Solventum Corporation | $44.73 | 2024-2025 | Activ.A.C. |
| Nabriva Therapeutics, Plc | $43.48 | 2021-2022 | |
| Kerecis Limited | $40.19 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Misonix INC | $36.33 | 2019-2021 | |
| Anika Therapeutics, INC. | $34.76 | 2021 | |
| Gramercy Extremity Orthopedics LLC | $33.10 | 2021 | |
| Journey Medical Corporation | $32.20 | 2019 | |
| Melinta Therapeutics, LLC | $29.22 | 2019-2020 | |
| Urgo Medical North America, LLC | $28.56 | 2025 | Urgok2 |
| Nevro Corp. | $26.09 | 2022 | |
| Impactortho, INC. | $25.71 | 2024 | |
| Polarityte, INC. | $25.14 | 2019 | |
| Aroa Biosurgery Incorporated | $23.80 | 2025 | |
| Hartmann USA, INC. | $22.76 | 2023 | Zetuvit Plus |
| Biowound Solutions, INC. | $21.24 | 2025 | Bio-Connekt |
| Innovation Technologies INC | $18.82 | 2024 | Irrisept |
| Mayne Pharma Commercial LLC | $16.91 | 2021 | |
| Biotissue Holdings INC. | $16.55 | 2021 | |
| Treace Medical Concepts, INC. | $15.91 | 2022 | |
| Ibsa Pharma INC. | $15.10 | 2023 | Tirosint, Licart |
| Goode Surgical INC | $13.75 | 2020 | |
| Integra Lifesciences Corporation | $13.42 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medela LLC | $13.42 | 2021 | |
| Trice Medical, INC. | $12.91 | 2022 | |
| Arthrosurface Incorporated | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pipher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.